#USA #San Diego #Crenessity #Neurocrine Biosciences #INGREZZA

Neurocrine Biosciences' Third-Quarter 2026 Financial Results

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced impressive financial results for the third quarter of 2026, concluding on September 30. This quarter marked a watershed moment for the biopharmaceutical company, as it achieved net product sales exceeding $1 billion for the first time, driven by high demand across its diverse portfolio of innovative medicines.

Dr. Kyle W. Gano, the CEO of Neurocrine, expressed enthusiasm about the company's performance, stating, "Our third quarter performance marks another important milestone in Neurocrine's evolution, with net product sales exceeding $1 billion for the first time... This continuous growth reinforces the strength of our strategy and expands our capacity to invest in innovation."

Financial Highlights

The company reported total revenues of $1.123 billion for Q3 2026, an increase of 41% compared to $795 million during the same period last year. The growth was driven largely by the following:

• - INGREZZA® (valbenazine) net product sales reached $801 million, up 17% year-over-year, showcasing double-digit volume growth coinciding with heightened demand.
• - CRENESSITY® (crinecerfont) saw net sales of $211 million, propelled by strong demand and robust reimbursement rates on dispensed prescriptions.
• - VYKAT® (diazoxide choline) XR generated sales of $107 million in Q3, supported by steady patient demand.

Neurocrine also raised its full-year guidance for INGREZZA from a previous range of $2.825 - $2.875 billion to $2.900 - $2.925 billion.

Recent Developments

In addition to financial achievements, the company is progressing well in its clinical pipeline:

• - Neurocrine initiated a Phase 1 first-in-human clinical study for NBIP-'1968, a novel investigational triple agonist, which is being considered as a potential treatment for obesity. This follows a similar initiation for another investigational compound, NBIP-'2118.
• - A Phase 2 clinical study has begun for NBI-'567, targeting cognitive impairment associated with Alzheimer's disease.
• - Data from the KINECT-PRO™ study demonstrated substantial Quality of Life improvements for patients using INGREZZA, indicating strong therapeutic value irrespective of underlying conditions.

Financial Position

As of September 30, 2026, the company reported a significant amount of cash, cash equivalents, and marketable securities totaling approximately $790 million. The company's overall financial health is evidenced by its performance statistics:

• - GAAP Net Income for Q3 was noted at $207 million, or $1.96 per diluted share.
• - Non-GAAP Net Income was reported at $347 million, or $3.29 per diluted share, accentuating the financial growth trajectory.

Despite a marginal decline in GAAP net income compared to Q3 2025, the overall upward trend in revenue and strategic investments in innovation suggests a promising outlook for Neurocrine.

Looking Ahead

As Neurocrine gears up for further growth into 2027, the company sees substantial opportunities in both existing products and their extensive pipeline. Significant clinical milestones are expected in the near future, signaling an optimistic horizon for the firm.

In conclusion, Neurocrine Biosciences is actively positioning itself not only as a leader in the biopharmaceutical industry but also as a robust innovator catering to a variety of neurological and psychiatric disorders. Prospective developments and revenue growth underscore the company's commitment to advancing health solutions for patients with unmet medical needs.